TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

(2012) Atocha Romero et al.   Clinical & Translational Oncology

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

(2012) George Fountzilas et al.   Journal of Translational Medicine

Multifactorial Approach to Predicting Resistance to Anthracyclines

(2011) Christine Desmedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

(2010) Gottfried E. Konecny et al.   BREAST CANCER RESEARCH AND TREATMENT

Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy

(2010) Michael F. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

AreHER2andTOP2AUseful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?

(2009) Kathleen I. Pritchard   JOURNAL OF CLINICAL ONCOLOGY

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

(2007) Alessandra Gennari et al.   JNCI-Journal of the National Cancer Institute